Dr. Ladha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
# NTT3459
Los Angeles, CA 90089Phone+1 323-865-3105Fax+1 612-904-4358
Education & Training
Hennepin HealthcareResidency, Internal Medicine, 2009 - 2012
Aga Khan Medical CollegeClass of 2007
Certifications & Licensure
CA State Medical License 2018 - 2026
NY State Medical License 2016 - 2019
WI State Medical License 2013 - 2017
MN State Medical License 2012 - 2015- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10 - Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.Karam Ashouri, Brian Hom, Anush A Ginosyan, Yekta Rahimi, Karen Resnick
British Journal of Haematology. 2024-12-01 - Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation.Dat Ngo, Jose Tinajero, Abdullah Ladha, Monzr M Al Malki, Salman Otoukesh
Transplantation and Cellular Therapy. 2024-11-01
Authored Content
- Hepatic Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients with Prior Exposure to Gemtuzumab Ozogamicin or Inotuzumab OzogamicinSeptember 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
